Citing Lack Of Infrastructure, Brakes Are Put On Allowing Phase I Trials In India
This article was originally published in PharmAsia News
MUMBAI - After building great expectations on allowing Phase I human studies in India, the government has now back tracked from taking any concrete decisions until the "right infrastructure" is put in place
You may also be interested in...
The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.
CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries
The Drug Controller General of India issued warning letters to U.S.-based Wyeth Pharmaceutical and a clinical trial monitor for violating Indian trial rules. The CDGI said an audit of a suspended trial of a pneumococcal vaccine in India disclosed violations of protocol, standard operating procedure and good clinical practices. The monitor was GVK Biosciences. DCGI ordered the trial suspended last November after the death of an infant, which the agency said protocol dictated should not have been included in the trial. The incident, involving a trial that began in 2007 with 350 children, is the first recorded in India. (Click here for more